Novartis Oncology
T-ONC-1242855 3/21
Breast Cancer
Novartis Oncology
CDK4/6 Inhibitor Option for HR+/HER2- mBC: Are All CDK4/6 Inhibitors the Same?
FEATURING
Dennis Slamon
- 1,686 views
- August 29, 2023
- 3
Novartis Oncology
CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Analyzing the Median OS Data
FEATURING
Gabriel Hortobagyi
- 2,179 views
- April 27, 2023
- 1
Novartis Oncology
The Importance of Dosing and Patient Adherence in HR+/HER2- mBC
FEATURING
Nick McAndrew
- 1,130 views
- June 28, 2023
- 2
Novartis Oncology
Discussion on Overall Survival Data Across 3 Phase III Trials in HR+/HER2- mBC
FEATURING
Gabriel Hortobagyi
- 2,065 views
- April 27, 2023
- 5
